Literature DB >> 31437057

Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study.

Noriko Fukuhara1, Go Yamamoto2, Hideki Tsujimura3, Takaaki Chou4, Hirohiko Shibayama5, Tomoko Yanai6, Kazunori Shibuya6, Koji Izutsu7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31437057     DOI： 10.1080/10428194.2019.1654100

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  7 in total

1.  Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma.

Authors:  Robert Chen; Alex F Herrera; Jessie Hou; Lu Chen; Jun Wu; Yuming Guo; Timothy W Synold; Vu N Ngo; Sandrine Puverel; Matthew Mei; Leslie Popplewell; Shuhua Yi; Joo Y Song; Shu Tao; Xiwei Wu; Wing C Chan; Stephen J Forman; Larry W Kwak; Steven T Rosen; Edward M Newman
Journal:  Clin Cancer Res       Date:  2019-12-06       Impact factor: 12.531

Review 2.  How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents.

Authors:  Julia Driessen; Sanne H Tonino; Alison J Moskowitz; Marie José Kersten
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

3.  Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma.

Authors:  Liudmila V Fedorova; Kirill V Lepik; Nikita P Volkov; Polina V Kotselyabina; Evgenia S Borzenkova; Marina O Popova; Anastasia V Beynarovich; Vadim V Baykov; Andrey V Kozlov; Ivan S Moiseev; Natalia B Mikhailova; Alexander D Kulagin
Journal:  Int J Clin Oncol       Date:  2021-11-26       Impact factor: 3.850

4.  Checkpoint Inhibition Therapy in Transplant-Ineligible Relapsed or Refractory Classic Hodgkin Lymphoma.

Authors:  Samer A Al-Hadidi; Hun Ju Lee
Journal:  JCO Oncol Pract       Date:  2021-01-12

Review 5.  Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma.

Authors:  Shinichi Makita; Dai Maruyama; Kensei Tobinai
Journal:  Onco Targets Ther       Date:  2020-06-23       Impact factor: 4.147

Review 6.  Primary Mediastinal B-Cell Lymphoma: Novel Precision Therapies and Future Directions.

Authors:  Huan Chen; Tao Pan; Yizi He; Ruolan Zeng; Yajun Li; Liming Yi; Hui Zang; Siwei Chen; Qintong Duan; Ling Xiao; Hui Zhou
Journal:  Front Oncol       Date:  2021-03-22       Impact factor: 6.244

7.  Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin.

Authors:  Ayana Uchimura; Hajime Yasuda; Jun Ando; Yasunori Ota; Makoto Sasaki; Tomoiku Takaku; Yutaka Tsukune; Miyuki Tsutsui; Yoko Edahiro; Naoki Watanabe; Tomonori Ochiai; Norio Komatsu; Miki Ando
Journal:  Case Rep Oncol       Date:  2022-03-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.